tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

AstraZeneca announces launch of Evinova, a digital health solutions provider

AstraZeneca (AZN) launches Evinova, set to be a leading provider of digital health solutions to better meet the needs of healthcare professionals, regulators and patients. With long-term backing from AstraZeneca and strategic collaborations with Parexel and Fortrea (FTRE), Evinova offers globally-scaled digital products and services to the life sciences and healthcare sector. Evinova will prioritise bringing to market established and scaled digital technology solutions already being used globally by AstraZeneca to optimise clinical trial design and delivery. This will reduce the time and cost of developing new medicines, bring care closer to home for patients and reduce the burden on health systems. Evinova will also pursue opportunities in digital remote patient monitoring and digital therapeutics with a pipeline of digital innovations in these areas. Pascal Soriot, Chief Executive Officer, AstraZeneca, said: “The future of medicine development can be accelerated with digital solutions. We believe Evinova’s combination of scientific expertise and track record in developing AI-enabled digital technologies at scale, provides a real opportunity to fundamentally improve patient care, drive healthcare transformation and reduce carbon emissions.” Evinova will combine clinical and regulatory experience gained at AstraZeneca with its deep expertise in digital technology spanning strategy and development, digital product development, data science and AI, user experience design and behavioural science.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See the top stocks recommended by analysts >>

Read More on AZN:

Disclaimer & DisclosureReport an Issue

1